سعر كيوروسيرف 80 مجم/مل معلق داخل الرغامى 3 مل 2023

Curosurf 80 mg/ml intratracheal suspension, 3 ml vial (240 mg poractant alfa); Chiesi via Pharma Overseas.

• Treatment (including early rescue) of Respiratory Distress Syndrome (RDS) / hyaline membrane disease in newborn babies; prophylactic use in premature infants requiring intubation who are at risk of RDS.Population: Premature / newborn infants with or at risk of RDSUK eMC / MHRA SmPC
• Rescue treatment of Respiratory Distress Syndrome (RDS) in premature infants; reduces mortality and pneumothoraces associated with RDS (US label).Population: Premature infants with RDSDailyMed (NLM)

• Reported reactions include sepsis, intracranial haemorrhage, pneumothorax (uncommon); bradycardia, hypotension, pulmonary haemorrhage, oxygen saturation decreased (rare); hyperoxia, apnoea, cyanosis (frequency not known). LISA technique associated with transient desaturation, apnoea, bradycardia.International label, same product · UK eMC / MHRA SmPC

• Hypersensitivity to the active substance or to any excipient. No other specific contraindications are yet known (UK SmPC).International label, same product · UK eMC / MHRA SmPC

• Administer only by personnel trained in care of preterm infants with continuous heart-rate and oxygenation monitoring. Rapid improvement in compliance/oxygenation requires prompt ventilator and FiO2 adjustment to avoid hyperoxia. Reflux, endotracheal obstruction, bradycardia/hypotension/desaturation: interrupt dosing and manage. Aspiration of tracheal secretions generally not recommended for at least 6 hours after administration except life-threatening situations.International label, same product · UK eMC / MHRA SmPC

• Not relevant — product indicated only in newborn infants (UK SmPC fertility/pregnancy/lactation section).International label, same product · UK eMC / MHRA SmPC

• Poractant alfa: Lowers alveolar surface tension, stabilising alveoli and improving lung compliance in surfactant-deficient premature infants (UK SmPC).